{"disease":{"id":"essential-thrombocythaemia","name":"essential thrombocythaemia"},"drugs":{"marketed":[{"drug_id":"fedratinib-hydrochloride","indication_name":"Post-essential thrombocythaemia myelofibrosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Inrebic","generic_name":"FEDRATINIB HYDROCHLORIDE","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"JAK2, FLT3","drug_class":"","quality_score":62,"revenue":null,"mechanism":"Fedratinib inhibits JAK2 and FLT3 kinases, reducing STAT3/5 phosphorylation and cell proliferation in MPNs."},{"drug_id":"fedratinib","indication_name":"Post-essential thrombocythaemia myelofibrosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Inrebic","generic_name":"FEDRATINIB","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Cyclin-G-associated kinase","drug_class":"","quality_score":75,"revenue":null,"mechanism":"Inrebic works by blocking the activity of Cyclin-G-associated kinase, a protein involved in the proliferation and survival of bone marrow cells."}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06923670","title":"Prevalence Of Germline Gene Mutations In Patients With Myeloproliferative Neoplasms With Family History","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":496,"lead_sponsor_name":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","has_results":false},{"nct_id":"NCT06514807","title":"A Study to Evaluate the Efficacy and Safety of Ropeginterferon Alfa-2b in Essential Thrombocythaemia Patients","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":117,"lead_sponsor_name":"AOP Orphan Pharmaceuticals AG","has_results":false},{"nct_id":"NCT00413634","title":"The Pharmacokinetics of Anagrelide in Elderly and Young Patients With Essential Thrombocythaemia (ET)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":24,"lead_sponsor_name":"Shire","has_results":true},{"nct_id":"NCT06786234","title":"A Phase 1 Study to Assess STP938 as a Monotherapy in Adults With High Risk Essential Thrombocythaemia","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":20,"lead_sponsor_name":"Step Pharma, SAS","has_results":false}],"total":4},"guidelines":[],"source":"Drug Landscape verified database"}